Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23869504 | 0.98 | NR1I2 (0.34) | DNM1NR1I2MAPTLMNASLC2A1 | |
| SCHEMBL21346764 | 0.98 | NR1I2 (0.34) | DNM1NR1I2MAPTLMNASLC2A1 | |
| SCHEMBL19965631 | 0.87 | NR1I2 (0.31) | NR1I2 | |
| SCHEMBL27100721 | 0.82 | DNM1 (0.34) | DNM1NR1I2LMNASLC2A1CA2 | |
| SCHEMBL19231984 | 0.82 | DNM1 (0.34) | DNM1NR1I2MAPTLMNASLC2A1 | |
| SCHEMBL22810433 | 0.81 | — | — | |
| SCHEMBL24805811 | 0.80 | DEGS1 (0.39) | NR1I2MAPTLMNA | |
| SCHEMBL19987514 | 0.80 | NR1I2 (0.34) | DNM1NR1I2MAPTLMNASLC2A1 | |
| SCHEMBL19134116 | 0.79 | DNM1 (0.38) | DNM1NR1I2LMNA | |
| SCHEMBL21725999 | 0.79 | POLB (0.33) | NR1I2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | DNM1 732/4885NR1I2 723/4885MAPT 4094/4885 |
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | DNM1 732/4885NR1I2 723/4885MAPT 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.